Abstract
Atopic dermatitis (AD) is a disease characterized by chronic skin inflammation and epidermal barrier dysfunction leading to decrease in patients' quality of life. AD is widespread in general population including children. This article covers the disease pathophysiological mechanisms including those that depend on the endotype, as well as core principles of systemic therapy for children with moderate and severe AD. Features of targeted therapy of such patients with dupilumab (IL-4 and IL-13 inhibitor) are presented. The studies' results on dupilumab efficacy and safety in the short- and long-term are shown.
Highlights
ВВЕДЕНИЕ Атопический дерматит (АтД) — хроническое воспалительное заболевание кожи, характеризующееся экзематозными поражениями и зудом, часто сопровождающееся внекожными аллергическими состояниями, что снижает качество жизни пациентов [1, 2]
Atopic dermatitis (AD) is a disease characterized by chronic skin inflammation and epidermal barrier dysfunction leading to decrease in patients’ quality of life
AD is widespread in general population including children
Summary
ВВЕДЕНИЕ Атопический дерматит (АтД) — хроническое воспалительное заболевание кожи, характеризующееся экзематозными поражениями и зудом, часто сопровождающееся внекожными аллергическими состояниями, что снижает качество жизни пациентов [1, 2]. For citation: Murashkin Nikolay N., Opryatin Leonid A., Epishev Roman V., Materikin Alexander I., Ambarchyan Eduard T., Ivanov Roman A., Fedorov Dmitriy V., Kukoleva Daria S. При этом у 50% пациентов с АтД отмечен Т2-эндотип воспаления, связанный с более тяжелым течением болезни [20,21,22].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
